Hillel Yaffe Medical Center   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3
Founded: Hadera Israel (1957)

Organization Overview

First Clinical Trial
2005
NCT00271791
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Hillel yaffe MC | Hillel Yaffe MC | Hillel Yaffe Medical Center

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 3)

Constriction, Pathologic (Phase 2)

Diarrhea (Phase 2)

Fatty Liver (Phase 2)

Guillain-Barre Syndrome (Phase 2)

Infections (Phase 3)

Infertility (Phase 3)

Infertility, Male (Phase 3)

Liver Diseases (Phase 2)

Metabolic Syndrome (Phase 2)

Neuritis (Phase 2)

Non-alcoholic Fatty Liver Disease (Phase 2)

Obstetric Labor Complications (Phase 3)

Premature Birth (Phase 3)

Sepsis (Phase 3)

Urethral Stricture (Phase 2)

Vestibular Diseases (Phase 2)

Vestibular Neuronitis (Phase 2)

Wound Infection (Phase 3)

Wounds and Injuries (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 39
  • # of Trial APIs: 45